News Feed Opinion Blog Posts Career Updates Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
August, 2025
August 2025
M T W T F S S
 123
45678910
11121314151617
18192021222324
25262728293031
Framework to Select Multi-Cancer Detection Assays for the Vanguard Study – NCI Division of Cancer Prevention
Photo: Depositphotos
Aug 13, 2025, 16:16

Framework to Select Multi-Cancer Detection Assays for the Vanguard Study – NCI Division of Cancer Prevention

NCI Division of Cancer Prevention shared a post on LinkedIn about recent paper published in Cancer Epidemiology, Biomarkers and Prevention.

“The National Cancer Institute (NCI), part of the National Institutes of Health (NIH), created an evaluation framework to select multi-cancer detection (MCD) assays for the Vanguard Study. Read the original research article in the August issue of Cancer Epidemiology, Biomarkers and Prevention.”

Title: Framework to Select Multi-Cancer Detection Assays in the National Cancer Institute’s Vanguard Study

Authors: Elyse LeeVan, Amanda L. Skarlupka, Christos Patriotis, Wendy S. Rubinstein, Paul F. Pinsky, Wade Bolton, Anthony Dickherber, Daniel C. Edelman, Lyndsay Harris, Hormuzd A. Katki, Erin B. Lavik, Albine Martin, Mary Jane C. Ong, Philip C. Prorok, David Ransohoff, Sarah M. Temkin, Lori M. Minasian

Read The Full Article at Cancer Epidemiology, Biomarkers and Prevention.

Framework to Select Multi-Cancer Detection Assays for the Vanguard Study - NCI Division of Cancer Prevention

More posts featuring NCI Division of Cancer Prevention.

 

Albine Martin Amanda L. Skarlupka Anthony Dickherber Christos Patriotis Daniel C. Edelman David Ransohoff Elyse LeeVan Erin B. Lavik Hormuzd A. Katki Lori M. Minasian Lyndsay Harris Mary Jane C. Ong NCI Division of Cancer Prevention Paul F. Pinsky Philip C. Prorok Sarah M. Temkin Wade Bolton Wendy S. Rubinstein
Special Coverage
Science
Aug 13, 2025, 16:16
Framework to Select Multi-Cancer Detection Assays for the Vanguard Study - NCI Division of Cancer Prevention
Science
Aug 13, 2025, 15:55
Francesco Massari: Words of Wisdom about nccRCC in European Urology
Science
Aug 13, 2025, 15:48
Myeloma Paper of the Day, August 13th, Suggested by Robert Orlowski
Insight
Aug 13, 2025, 15:36
Dora Vallejo-Ardila: Highlights from First Day of MOGA 2025
Voices
Aug 13, 2025, 15:34
Sameer Keole: Privilege of Being ASTRO President Is Meeting Talented People I’d Not Met Otherwise
Voices
Aug 13, 2025, 15:32
Diana Adams: Medical Oncology Group of Australia (MOGA)⁩ Session on Increasing Workforce Pressure
Voices
Aug 13, 2025, 15:30
Proud to be No.1 in Hypertension and No.6 in Cardiology Worldwide - Servier
Voices
Aug 13, 2025, 15:29
Stefano Magno: Integrative Oncology Teams to Bridge Oncology and Primary Care
Science
Aug 13, 2025, 15:26
Arndt Vogel: Interesting Analysis on Potential Biomarkers to Guide Adjuvant Treatment
Voices
Aug 13, 2025, 15:25
Yvonne Diaz: Survival Rates for the Deadliest Cancers
Insight
Aug 13, 2025, 15:20
Amol Akhade: KEYNOTE-905 - Potential Practice Changer in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer
Blog Posts
Aug 13, 2025, 15:18
Ryan Nipp: Patient-Reported Symptoms Linked to Emergency Care in Chemotherapy